Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
New Workflow Is First End-to-End Solution For Extrusion-Based Drug Implant Production | ||
By: PR Newswire Association LLC. - 26 Jul 2017 | Back to overview list |
|
KARLSRUHE, Germany, July 26, 2017 /PRNewswire/ -- To meet growing demand for innovative drug delivery systems in the pharmaceutical industry, drug formulation scientists can now use the first commercially available, fully-integrated solution for polymer-based drug implant development and production using hot melt extrusion (HME). This new drug development workflow provides pharmaceutical manufacturers with a complete end-to-end manufacturing line from a single supplier. The Thermo Scientific Pharma mini implant line is built around the Thermo Scientific Pharma mini HME twin-screw micro compounder. It provides drug developers, process manufacturing scientists and engineers with a continuous and fast production process designed to improve product quality, maximize operator safety and reduce the risk of contamination. This integrated production line is also designed to allow contract research and manufacturing organizations (CRO/CMO) to develop and optimize small-scale formulations before engaging in larger-scale production. "With a single subcutaneous injection, advanced drug implants can release a therapeutic substance that can provide patients with improved drug compliance, effective disease treatment or controlled hormonal regulation for weeks or even months," said Hanna Granö-Fabritius, senior business director, material characterization for Thermo Fisher Scientific. "Pharmaceutical manufacturers are seeking fast, reliable solutions for continuous production of novel drug delivery systems. Our new, automated implant line offers a hot melt extrusion solution designed to minimize formulation development time." The Thermo Scientific Pharma mini implant line incorporates a range of components in an innovative configuration. In addition to the Pharma mini HME micro compounder, components include:
For more information on the Thermo Scientific Pharma mini implant line, please visit www.thermofisher.com/implantline. About Thermo Fisher Scientific Media Contact Information: Brian Lowe Jim Heeren
View original content with multimedia:http://www.prnewswire.com/news-releases/new-workflow-is-first-end-to-end-solution-for-extrusion-based-drug-implant-production-300494793.html SOURCE Thermo Fisher Scientific Inc. |
||
|
||
Copyright 2017 PR Newswire Association LLC. | Back to overview list |